Amoxicillin-Clavulanate ER 1000-62.5 mg for Respiratory Infections
For respiratory tract infections in otherwise healthy adults, the amoxicillin-clavulanate ER 1000-62.5 mg formulation should be dosed as two tablets (2000 mg/125 mg total) twice daily for 7-10 days, taken at the start of meals. 1
Dosing Recommendations
The FDA-approved dosing for the extended-release formulation specifically addresses respiratory infections:
- Dose: Two 1000 mg/62.5 mg ER tablets twice daily (total daily dose: 4000 mg amoxicillin/250 mg clavulanate)
- Timing: Administer at the start of meals to enhance clavulanate absorption and minimize gastrointestinal side effects 1
- Duration: 7-10 days for most respiratory infections 2
Clinical Context and Evidence
For Community-Acquired Pneumonia (CAP)
The 2019 IDSA/ATS guidelines recommend amoxicillin-clavulanate as part of combination therapy for outpatients with comorbidities (chronic heart, lung, liver, or renal disease; diabetes; alcoholism; malignancy; asplenia). The standard dosing in guidelines references 875 mg/125 mg twice daily or 2000 mg/125 mg twice daily formulations 3. The ER formulation at 2000 mg/125 mg twice daily aligns with the higher-dose recommendation for respiratory tract infections.
A large multicenter study of 709 CAP patients demonstrated that amoxicillin-clavulanate 1000/62.5 mg twice daily for 10 days achieved:
- 94.9% clinical recovery rate
- 94.3% bacteriological success
- 98.7% radiological improvement
- Only 8.6% experienced mild-to-moderate diarrhea 2
Duration Considerations
Recent evidence supports 5-7 days as adequate for most non-ICU CAP and acute exacerbations of COPD in patients showing clinical improvement 4. However, the ER formulation studies specifically used 7-10 day courses 2, 5, and this remains the FDA-supported duration for respiratory infections 1.
For practical application: Start with 7 days and extend to 10 days only if clinical response is slower than expected or if dealing with more severe infection.
Important Caveats
Formulation-Specific Warnings
The ER 1000-62.5 mg formulation is NOT interchangeable with standard immediate-release formulations due to different clavulanate ratios. The ER formulation contains significantly less clavulanate (62.5 mg vs 125 mg) but achieves adequate coverage through extended-release pharmacokinetics 1.
Patient Selection
This dosing applies to:
- Adults without comorbidities: May use as monotherapy for less severe respiratory infections
- Adults with comorbidities: Should combine with a macrolide (azithromycin or clarithromycin) or doxycycline per IDSA/ATS guidelines 3
- Healthy adults: Consider if beta-lactamase-producing organisms (H. influenzae, M. catarrhalis) are suspected 6
Contraindications to This Specific Formulation
Do not use the ER formulation if:
- Patient requires more than 125 mg clavulanate per dose (use standard 875/125 mg formulation instead)
- Severe renal impairment (requires dose adjustment not well-established for ER formulation)
- Patient cannot swallow tablets whole (ER tablets must not be crushed)
Safety Profile
The ER formulation demonstrates favorable tolerability with predominantly mild-to-moderate gastrointestinal effects (8.6% diarrhea rate) 2. Recent safety data from 2025 confirms excellent tolerability with 87.5% of adverse events resolving spontaneously 5.
Stewardship Considerations
Amoxicillin-clavulanate is classified in the WHO AWaRe "Access" category, making it a preferred first-line agent that balances efficacy with lower resistance selection pressure compared to fluoroquinolones or macrolides 6. This positioning supports its use as a cornerstone antibiotic for respiratory infections when bacterial etiology is confirmed or highly suspected.